DMK Pharmaceuticals (LTS:0A4X) Total Assets : $8.96 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is DMK Pharmaceuticals Total Assets?

DMK Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 was $8.96 Mil.

During the past 12 months, DMK Pharmaceuticals's average Total Assets Growth Rate was -76.40% per year. During the past 3 years, the average Total Assets Growth Rate was -36.80% per year. During the past 5 years, the average Total Assets Growth Rate was -23.90% per year. During the past 10 years, the average Total Assets Growth Rate was 46.00% per year.

During the past 13 years, DMK Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 357.90%. The lowest was -80.10%. And the median was -3.10%.

Total Assets is connected with ROA %. DMK Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2023 was -81.02%. Total Assets is also linked to Revenue through Asset Turnover. DMK Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

DMK Pharmaceuticals Total Assets Historical Data

The historical data trend for DMK Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Total Assets Chart

DMK Pharmaceuticals Annual Data

Trend

Mar13

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

58.36

47.84

30.87

38.30

10.93

DMK Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Assets	Get a 7-Day Free Trial															12.14	10.93	9.08	4.75	8.96

DMK Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

DMK Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	-0.808	+	11.739
	=	10.93

DMK Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2023 )	+	Total Liabilities (Q: Sep. 2023 )
	=	-5.295	+	14.252
	=	8.96

DMK Pharmaceuticals (LTS:0A4X) Total Assets Explanation

Total Assets is connected with ROA %.

DMK Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2023 is

ROA %	=	Net Income (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	-5.552	/	( (4.749	+	8.957)	/ 2 )
	=	-5.552	/	6.853
	=	-81.02 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

DMK Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2023 is

	Asset Turnover
=	Revenue (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
=	0.009	/	( (4.749	+	8.957)	/ 2 )
=	0.009	/	6.853
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

DMK Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

DMK Pharmaceuticals (LTS:0A4X) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (LTS:0A4X) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

DMK:USA

Address

11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130

Website

https://www.adamispharmaceuticals.com

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

DMK Pharmaceuticals (LTS:0A4X) Headlines

No Headlines